Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer

SIMPLE SUMMARY: Safety and pre-existing or acquired resistance to treatments limit the clinical benefit of most drugs against breast cancer. Great effort has been made to mitigate the limitations of combined drug treatment. We here explored the effect of the combination of ribitol, a sugar metabolit...

Descripción completa

Detalles Bibliográficos
Autores principales: Doddapaneni, Ravi, Tucker, Jason D., Lu, Pei J., Lu, Qi L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486979/
https://www.ncbi.nlm.nih.gov/pubmed/37686632
http://dx.doi.org/10.3390/cancers15174356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486979/
https://www.ncbi.nlm.nih.gov/pubmed/37686632
http://dx.doi.org/10.3390/cancers15174356

Ejemplares similares